Home » Stocks » AKRX

Akorn, Inc. (AKRX)

Jun 1, 2020 - AKRX was delisted due to bankruptcy and now trades as AKRXQ
Stock Price: $0.0900 USD 0.0000 (0.00%)
Updated May 29, 2020 4:00 PM EDT
Market Cap 11.98M
Revenue (ttm) 721.25M
Net Income (ttm) -401.30M
Shares Out 133.15M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 29, 2020
Last Price $0.0900
Previous Close $0.0900
Change ($) 0.0000
Change (%) 0.00%
Day's Open 0.1800
Day's Range 0.0900 - 0.1950
Day's Volume 36,138,501
52-Week Range 0.0900 - 5.4600

News

Hide News
PRNewsWire - 6 months ago

LAKE FOREST, Ill., Sept. 2, 2020 /PRNewswire/ -- Akorn, Inc.

GlobeNewsWire - 6 months ago

LAKE FOREST, Ill., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (The OTC Pink Market: AKRXQ), a leading specialty pharmaceutical company, today announced its financial results for the secon...

PRNewsWire - 9 months ago

LAKE FOREST, Ill., May 20, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company ("Akorn" or the "Company"), today announced that the Company and its U.S....

Zacks Investment Research - 1 year ago

Akorn's (AKRX) fourth-quarter 2019 results are likely to reflect a decline in sales volume due to stiffening competition.

Seeking Alpha - 1 year ago

Akorn And Conn: High Risk And High Reward

Zacks Investment Research - 1 year ago

Akorn, Inc. (AKRX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Market Watch - 1 year ago

Shares of drug maker Akorn Inc. AKRX, -23.27% plunged 27% on heavy volume toward a record low, to extend the sharp selloff this week, after the company disclosed it was considering filing for ...

Seeking Alpha - 1 year ago

Akorn Warns Of Possible Bankruptcy Filing

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that Akorn and certain of its lenders have reache...

Zacks Investment Research - 1 year ago

Akorn (AKRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 1 year ago

Shares of generic drugmakers rose on Monday on a possible end to the persistent price-fixing probe.

Other stocks mentioned: BHC, TEVA, ZYNE
Zacks Investment Research - 1 year ago

Despite the slow pace of movement of small-cap stock prices, a few stocks within this stable have skyrocketed ahead of the large-cap-centric indexes this year.

Other stocks mentioned: BBSI, CHUY, FRTA, NX
Seeking Alpha - 1 year ago

Akorn, Inc. (AKRX) CEO Douglas Boothe on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Akorn (AKRX) delivered earnings and revenue surprises of 150.00% and 0.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Akorn (AKRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it received a new Abbreviated New Drug Appli...

Seeking Alpha - 1 year ago

Akorn is a pharmaceutical company designing and selling generic and branded prescription pharmaceuticals as well as consumer and animal health products.

GlobeNewsWire - 1 year ago

LAKE FOREST, Ill., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Dr...

Seeking Alpha - 1 year ago

Akorn, Inc. (AKRX) CEO Douglas Boothe on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Akorn (AKRX) delivered earnings and revenue surprises of 66.67% and 3.27%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Akorn (AKRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 1 year ago

Generic pharmaceuticals manufacturer Akorn, Inc. (NASDAQ: AKRX) said Tuesday that it received a warning letter from the Food and Drug Administration related to the inspection of its Somerset, ...

24/7 Wall Street - 1 year ago

Akorn Inc. shares dipped on Tuesday after the firm announced that it received a warning letter from the U.S. Food and Drug Administration.

Market Watch - 1 year ago

Generics company Akorn Inc. said Tuesday it has received a warnings letter from the U.S. Food and Drug Administration, relating to the inspection of a facility in New Jersey in July and August...

Seeking Alpha - 1 year ago

Akorn, Inc. (AKRX) CEO Douglas Boothe on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Akorn (AKRX) delivered earnings and revenue surprises of 28.57% and 8.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 1 year ago

The embattled generic-pharmaceutical manufacturer earned two new product approvals.

Benzinga - 1 year ago

Shares of specialty generic pharma company Akorn, Inc. (NASDAQ: AKRX) are advancing solidly Monday morning thanks to twin announcements announced late last week.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Akorn (AKRX) stock based on the movements in the options market lately.

About AKRX

Akorn, a specialty pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquid... [Read more...]

Industry
Drug Manufacturers—Specialty & Generic
Founded
1971
CEO
Douglas S. Boothe
Employees
2,227
Stock Exchange
NASDAQ
Ticker Symbol
AKRX
Full Company Profile

Financial Performance

In 2019, Akorn's revenue was $682.43 million, a decrease of -1.67% compared to the previous year's $694.02 million. Losses were -$226.77 million, -43.58% less than in 2018.

Financial Statements